Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   
X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CEBPA (CCAAT enhancer binding protein alpha)

Identity

Other namesC/EBPa
HGNC (Hugo) CEBPA
LocusID (NCBI) 1050
Location 19q13.11
Location_base_pair Starts at 33790840 and ends at 33793430 bp from pter ( according to hg19-Feb_2009)  [Mapping]

DNA/RNA

Description CEBPA is a single exon gene located on the minus strand of chromosome 19q.
Transcription The mRNA produced consists of a short 5'UTR containing a small 5'ORF, the coding region and a large 3'UTR.

Protein

 
  C/EBPa protein domains
The basic region leucine zipper domain mediates DNA binding, homodimerization of C/EBPa and heterodimerization with other members of the C/EBP family. This region is also involved in mediating protein-protein interactions with other transcription factors involved in lineage determination and growth proliferation. N-terminal region transactivating domains mediate interactions with transcriptional machinery and proteins important in cell cycle control.
The CEBPA mRNA gives rise to two different translational isoforms by using different start codons within the same open reading frame by means of leaky ribosome scanning; the full length 42kDa protein and a 30kDa truncated form. These isoforms display contrasting functions in regards to gene activation and cell proliferation. Both isoforms can be detected within the cell and it is likely that the ratio of isoforms is important in mediating proliferation and differentiation control.
Expression C/EBPa is expressed in many cell types and plays crucial roles in hepatocyte and adipocyte development, with highest concentrations in terminally differentiated cells. In hematopoiesis, C/EBPa is expressed in myeloid cells and drives granulocytic differentiation. C/EBPa is also found expressed in intestine, lung, adrenal gland, breast, ovary and placenta tissues.
Localisation C/EBPa localises to the nucleus
Function C/EBPa and its isoforms play important roles in lineage determination and gene activation in a variety of cell types by activating transcription from lineage-specific promoters. In hematopoiesis, C/EBPa is a key factor in driving the development of myeloid cells interacting with a variety of factors, including c-Myc, PU.1, and microRNAs. The truncated form of C/EBPa has been seen to act in a dominant negative regulatory manner in mice, abolishing normal C/EBPa function and causing a block in differentiation. In humans, the truncated protein selectively inhibits C/EBPa DNA binding but due to variable DNA affinity has a greater range of effects on differentiation.
Several pathways have been implicated as the means by which C/EBPa mediates cell cycle arrest and proliferation, including p21, cyclin-dependent kinases and the E2F complex via c-Myc. The 30kDa isoform of C/EBPa lacks the domains required to mediate cell growth.
Homology C/EBPa belongs to the family of C/EBP proteins and is conserved across a variety of vertebrate species

Mutations

Note Mutations in CEBPA occur in approximately 10% of all acute myeloid leukemias (AMLs)
 
  N-terminal mutations abolish expression of full length 42kDa protein, upregulating production of the 30kDa isoform.
C-terminal mutations result in C/EBPa proteins with decreased DNA binding or dimerization activity.
Germinal Germline mutations in CEBPA have been described in 2 familial cases of AML. The first family contained a heterozygous germline mutation of del (C) at nucleotide 212 which causes the premature termination of the protein at codon 158. The 30kDa isoform is produced. Somatic mutation causing in frame duplication was also found in the C-terminal region of one patient on the other allele, which was not present in remission samples. The second family contained a heterozygous germline mutation of ins (C) at nucleotide 217 which causes the premature termination of the protein. The 30kDa isoform is produced. Somatic mutations in the C-terminal region were found in two of the affected family members.
Somatic Mutations in CEBPA tend to cluster to two regions.
The first group affect the N-terminal region of C/EBPa. These mutations are often insertions or deletions which cause frameshifts which cause premature truncation of the protein. In this case, translation is reinitiated at an internal ATG and the 30kDa protein, which lacks the first transactivating domain, is produced.
Secondly, in-frame or missense mutations occur within the C-terminal region of C/EBPa, disrupting the basic zipper region and thus affecting DNA binding, protein interactions as well as homo and heterodimerization with other C/EBP family members.
Multiple mutations in CEBPA are common and often biallelic, although the allelic frequency of the mutations can change over the course of the disease. Mutations are generally maintained between presentation and replapse and therefore may be useful for monitoring minimal residual disease.

Implicated in

Entity Acute myeloid leukemias
Disease Mutations in CEBPA have been implicated in acute myeloid leukaemia, most often in association with FAB types M1 and M2, although it has also been found in M4 and M5 types. Mutations in CEBPA occur in approximately 10% of all AMLs and are associated with normal karyotype AML.
Prognosis Mutations in CEBPA tend to confer favourable prognosis. Low levels of RNA expression of CEBPA have been noted in AML where it may reflect adverse prognosis.
Oncogenesis CEBPA expression is downregulated in the presence of fusion protein AML1-ETO via inhibition of the CEBPA promoter.
Translation of the C/EBPa protein is suppressed by the fusion gene AML1-MDS1-EVI1 via the activation of calreticulin.
Pericentric inversion of chromosome 16, inv(16)(p13q22), which fuses the CBFB and MYH11 genes, with the latter encoding the smooth muscle myosin heavy chain (SMMHC) suppresses translation of the C/EBPa protein via calreticulin.
BCR-ABL fusion is able to suppress CEBPA protein translation via inhibitory action of the poly(rC)-binding protein hnRNP E2.
The involvement of CEBPA mutations in familial cases of AML, along with evidence of mutations persisting between presentation and relapse indicate that mutations in CEBPA are an early event in leukaemogenesis.
  
Entity Although mutated CEBPA is primarily observed in AML, in rare cases it has been found to be mutated in myelodysplasic syndromes (MDS), lung tumours and prostate tumours. Down-regulation of CEBPA has also been observed in blast crisis chronic myeloid leukaemia, lung cancer, breast cancer and liver cancer.
  
Entity t(14;19)(q32;q13) --> IGH / CEBPA
Disease CEBPA is rarely involved in translocations with other genes. However, in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) the 3'UTR of CEBPA has been found to be translocated to the immunoglobulin heavy chain locus
  

External links

Nomenclature
HGNC (Hugo)CEBPA   1833
Entrez_Gene (NCBI)CEBPA  1050  CCAAT/enhancer binding protein (C/EBP), alpha
Cards
AtlasCEBPAID40050ch19q13
GeneCards (Weizmann)CEBPA
Ensembl (Hinxton)ENSG00000245848 [Gene_View]  chr19:33790840-33793430 [Contig_View]  CEBPA [Vega]
AceView (NCBI)CEBPA
Genatlas (Paris)CEBPA
SOURCE (Stanford)NM_004364
Genomic and cartography
GoldenPath (UCSC)CEBPA  -  19q13.11   chr19:33790840-33793430 -  19q13.1   [Description]    (hg19-Feb_2009)
EnsemblCEBPA - 19q13.1 [CytoView]
Mapping of homologs : NCBICEBPA [Mapview]
OMIM116897   601626   
Gene and transcription
Genbank (Entrez)BC027902 BC063874 BC160133 X87248 Y11525
RefSeq transcript (SRS)NM_004364
RefSeq transcript (Entrez)NM_004364
RefSeq genomic (SRS)AC_000151 NC_000019 NC_018930 NG_012022 NT_011109 NW_001838492 NW_004078099
RefSeq genomic (Entrez)AC_000151 NC_000019 NC_018930 NG_012022 NT_011109 NW_001838492 NW_004078099
Consensus coding sequences : CCDS (NCBI)CEBPA
Cluster EST : UnigeneHs.76171 [ SRS ] Hs.76171 [ NCBI ]
CGAP (NCI)Hs.76171
Alternative Splicing GalleryENSG00000245848
Gene ExpressionCEBPA [ NCBI-GEO ]   CEBPA [ EBI - ARRAY_EXPRESS ]
Protein : pattern, domain, 3D structure
UniProt/SwissProtP49715 (SRS) P49715 (Uniprot)
NextProtP49715
With graphics : InterProP49715
Splice isoforms : SwissVarP49715(Swissvar)
Domaine pattern : Prosite (SRS)BZIP (PS50217)    BZIP_BASIC (PS00036)   
Domaine pattern : Prosite (Expaxy)BZIP (PS50217)    BZIP_BASIC (PS00036)   
Domains : Interpro (SRS)bZIP    CCAAT/enhancer-binding   
Domains : Interpro (EBI)bZIP    CCAAT/enhancer-binding   
Related proteins : CluSTrP49715
Domain families : Pfam (SRS)bZIP_2 (PF07716)   
Domain families : Pfam (Sanger)bZIP_2 (PF07716)   
Domain families : Pfam (NCBI)pfam07716   
Domain families : Smart (EMBL)BRLZ (SM00338)  
DMDM1050
Blocks (Seattle)P49715
Human Protein AtlasENSG00000245848
HPRD00296
IPIIPI00292025   
Protein Interaction databases
DIP (DOE-UCLA)P49715
IntAct (EBI)P49715
FunCoupENSG00000245848
REACTOMECEBPA
Protein Interaction Database1050
BioGRIDCEBPA
InParanoidP49715
Interologous Interaction database P49715
IntegromeDBCEBPA
Polymorphism : SNP, mutations, diseases
SNP Single Nucleotide Polymorphism (NCBI)CEBPA
SNP (GeneSNP Utah)CEBPA
SNP : HGBaseCEBPA
Genetic variants : HAPMAPCEBPA
Cancer Gene: CensusCEBPA 
Somatic Mutations in Cancer : COSMICCEBPA 
CONAN: Copy Number AnalysisCEBPA 
Mutations and Diseases : HGMDCEBPA
OMIM116897    601626   
GENETests116897    601626   
Disease Genetic AssociationCEBPA
Huge Navigator CEBPA [HugePedia]  CEBPA [HugeCancerGEM]
Genomic VariantsCEBPA  CEBPA [DGVbeta]
ClinVarCEBPA
snp3D : Map Gene to Disease1050
General knowledge
Homologs : HomoloGeneCEBPA
Homology/Alignments : Family Browser (UCSC)CEBPA
Phylogenetic Trees/Animal Genes : TreeFamCEBPA
Chemical/Protein Interactions : CTD1050
Chemical/Pharm GKB GenePA26376
Clinical trialCEBPA
Cancer Resource (Charite)ENSG00000245848
Ontology : AmiGOurea cycle  negative regulation of transcription from RNA polymerase II promoter  liver development  embryonic placenta development  DNA binding  sequence-specific DNA binding transcription factor activity  RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity  protein binding  nucleus  generation of precursor metabolites and energy  transcription, DNA-dependent  transcription, DNA-dependent  transcription from RNA polymerase II promoter  acute-phase response  mitochondrion organization  transcription factor binding  cholesterol metabolic process  negative regulation of cell proliferation  nuclear matrix  virus-host interaction  cytokine-mediated signaling pathway  myeloid cell differentiation  macrophage differentiation  lung development  organ regeneration  protein complex binding  response to vitamin B2  Rb-E2F complex  protein homodimerization activity  sequence-specific DNA binding  transcription regulatory region DNA binding  positive regulation of fat cell differentiation  positive regulation of osteoblast differentiation  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase III promoter  protein heterodimerization activity  cell maturation  inner ear development  white fat cell differentiation  brown fat cell differentiation  response to glucocorticoid stimulus  cellular response to lithium ion  cellular response to organic cyclic compound  HMG box domain binding  
Ontology : EGO-EBIurea cycle  negative regulation of transcription from RNA polymerase II promoter  liver development  embryonic placenta development  DNA binding  sequence-specific DNA binding transcription factor activity  RNA polymerase II distal enhancer sequence-specific DNA binding transcription factor activity  protein binding  nucleus  generation of precursor metabolites and energy  transcription, DNA-dependent  transcription, DNA-dependent  transcription from RNA polymerase II promoter  acute-phase response  mitochondrion organization  transcription factor binding  cholesterol metabolic process  negative regulation of cell proliferation  nuclear matrix  virus-host interaction  cytokine-mediated signaling pathway  myeloid cell differentiation  macrophage differentiation  lung development  organ regeneration  protein complex binding  response to vitamin B2  Rb-E2F complex  protein homodimerization activity  sequence-specific DNA binding  transcription regulatory region DNA binding  positive regulation of fat cell differentiation  positive regulation of osteoblast differentiation  positive regulation of transcription from RNA polymerase II promoter  positive regulation of transcription from RNA polymerase III promoter  protein heterodimerization activity  cell maturation  inner ear development  white fat cell differentiation  brown fat cell differentiation  response to glucocorticoid stimulus  cellular response to lithium ion  cellular response to organic cyclic compound  HMG box domain binding  
Pathways : BIOCARTAMAPKinase Signaling Pathway [Genes]    Keratinocyte Differentiation [Genes]   
Other databases
Probes
Litterature
PubMed280 Pubmed reference(s) in Entrez
PubGeneCEBPA
iHOPCEBPA

Bibliography

The CCAAT/enhancer binding protein (C/EBP alpha) gene (CEBPA) maps to human chromosome 19q13.1 and the related nuclear factor NF-IL6 (C/EBP beta) gene (CEBPB) maps to human chromosome 20q13.1.
Hendricks-Taylor LR, Bachinski LL, Siciliano MJ, Fertitta A, Trask B, de Jong PJ, Ledbetter DH, Darlington GJ
Genomics. 1992 ; 14 (1) : 12-17.
PMID 1427819
 
PU.1 (Spi-1) and C/EBP alpha regulate expression of the granulocyte-macrophage colony-stimulating factor receptor alpha gene.
Hohaus S, Petrovick MS, Voso MT, Sun Z, Zhang DE, Tenen DG
Molecular and cellular biology. 1995 ; 15 (10) : 5830-5845.
PMID 7565736
 
C/EBP, c-Myb, and PU.1 cooperate to regulate the neutrophil elastase promoter.
Oelgeschlˆ§ger M, Nuchprayoon I, Lˆşscher B, Friedman AD
Molecular and cellular biology. 1996 ; 16 (9) : 4717-4725.
PMID 8756629
 
PU.1 (Spi-1) and C/EBP alpha regulate the granulocyte colony-stimulating factor receptor promoter in myeloid cells.
Smith LT, Hohaus S, Gonzalez DA, Dziennis SE, Tenen DG
Blood. 1996 ; 88 (4) : 1234-1247.
PMID 8695841
 
Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.
Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG
Proceedings of the National Academy of Sciences of the United States of America. 1997 ; 94 (2) : 569-574.
PMID 9012825
 
Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1.
Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE
Molecular and cellular biology. 1998 ; 18 (7) : 3915-3925.
PMID 9632776
 
C/EBPalpha bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts.
Wang X, Scott E, Sawyers CL, Friedman AD
Blood. 1999 ; 94 (2) : 560-571.
PMID 10397723
 
Translational control of C/EBPalpha and C/EBPbeta isoform expression.
Calkhoven CF, Mˆşller C, Leutz A
Genes & development. 2000 ; 14 (15) : 1920-1932.
PMID 10921906
 
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
Pabst T, Mueller BU, Harakawa N, Schoch C, Haferlach T, Behre G, Hiddemann W, Zhang DE, Tenen DG
Nature medicine. 2001 ; 7 (4) : 444-451.
PMID 11283671
 
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, Behre G, Hiddemann W, Tenen DG
Nature genetics. 2001 ; 27 (3) : 263-270.
PMID 11242107
 
Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
Gombart AF, Hofmann WK, Kawano S, Takeuchi S, Krug U, Kwok SH, Larsen RJ, Asou H, Miller CW, Hoelzer D, Koeffler HP
Blood. 2002 ; 99 (4) : 1332-1340.
PMID 11830484
 
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Perrotti D, Cesi V, Trotta R, Guerzoni C, Santilli G, Campbell K, Iervolino A, Condorelli F, Gambacorti-Passerini C, Caligiuri MA, Calabretta B
Nature genetics. 2002 ; 30 (1) : 48-58.
PMID 11753385
 
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, ALFA Group, Dombret H
Blood. 2002 ; 100 (8) : 2717-2723.
PMID 12351377
 
CCAAT/enhancer-binding proteins: structure, function and regulation.
Ramji DP, Foka P
The Biochemical journal. 2002 ; 365 (Pt 3) : 561-575.
PMID 12006103
 
Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.
Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, Meijer J, van Oosterhoud S, van Putten WL, Valk PJ, Berna Beverloo H, Tenen DG, Lˆwenberg B, Delwel R
The hematology journal : the official journal of the European Haematology Association / EHA. 2003 ; 4 (1) : 31-40.
PMID 12692518
 
The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells.
D'Alo' F, Johansen LM, Nelson EA, Radomska HS, Evans EK, Zhang P, Nerlov C, Tenen DG
Blood. 2003 ; 102 (9) : 3163-3171.
PMID 12869508
 
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
Snaddon J, Smith ML, Neat M, Cambal-Parrales M, Dixon-McIver A, Arch R, Amess JA, Rohatiner AZ, Lister TA, Fitzgibbon J
Genes, chromosomes & cancer. 2003 ; 37 (1) : 72-78.
PMID 12661007
 
Evidence for allelic evolution of C/EBPalpha mutations in acute myeloid leukaemia.
Tiesmeier J, Czwalinna A, Mˆşller-Tidow C, Krauter J, Serve H, Heil G, Ganser A, Verbeek W
British journal of haematology. 2003 ; 123 (3) : 413-419.
PMID 14616999
 
C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.
Cleaves R, Wang QF, Friedman AD
Oncogene. 2004 ; 23 (3) : 716-725.
PMID 14737106
 
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Frˆhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, Tobis K, Dˆhner H, Dˆhner K
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 ; 22 (4) : 624-633.
PMID 14726504
 
Disruption of C/EBPalpha function in acute myeloid leukemia.
Frˆhling S, Dˆhner H
The New England journal of medicine. 2004 ; 351 (23) : 2370-2372.
PMID 15575052
 
The leukemic fusion gene AML1-MDS1-EVI1 suppresses CEBPA in acute myeloid leukemia by activation of Calreticulin.
Helbling D, Mueller BU, Timchenko NA, Hagemeijer A, Jotterand M, Meyer-Monard S, Lister A, Rowley JD, Huegli B, Fey MF, Pabst T
Proceedings of the National Academy of Sciences of the United States of America. 2004 ; 101 (36) : 13312-13317.
PMID 15326310
 
The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest.
Mˆşller C, Calkhoven CF, Sha X, Leutz A
The Journal of biological chemistry. 2004 ; 279 (8) : 7353-7358.
PMID 14660596
 
C/EBPalpha mutations in acute myeloid leukaemias.
Nerlov C
Nature reviews. Cancer. 2004 ; 4 (5) : 394-400.
PMID 15122210
 
A dominant-negative mutant of C/EBPalpha, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse.
Schwieger M, Lˆhler J, Fischer M, Herwig U, Tenen DG, Stocking C
Blood. 2004 ; 103 (7) : 2744-2752.
PMID 14656889
 
Mutation of CEBPA in familial acute myeloid leukemia.
Smith ML, Cavenagh JD, Lister TA, Fitzgibbon J
The New England journal of medicine. 2004 ; 351 (23) : 2403-2407.
PMID 15575056
 
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.
Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, Akashi K, Tenen DG
Immunity. 2004 ; 21 (6) : 853-863.
PMID 15589173
 
A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis.
Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I
Cell. 2005 ; 123 (5) : 819-831.
PMID 16325577
 
Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer.
Gery S, Tanosaki S, Bose S, Bose N, Vadgama J, Koeffler HP
Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (9) : 3184-3190.
PMID 15867211
 
Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.
Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG
International journal of hematology. 2005 ; 81 (5) : 368-377.
PMID 16158816
 
CEBPA point mutations in hematological malignancies.
Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (3) : 329-334.
PMID 15674366
 
Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells.
Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, Shen HL, Su FH, Yao M, Huang SY, Tien HF
Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (4) : 1372-1379.
PMID 15746035
 
CBFB-SMMHC is correlated with increased calreticulin expression and suppresses the granulocytic differentiation factor CEBPA in AML with inv(16).
Helbling D, Mueller BU, Timchenko NA, Schardt J, Eyer M, Betts DR, Jotterand M, Meyer-Monard S, Fey MF, Pabst T
Blood. 2005 ; 106 (4) : 1369-1375.
PMID 15855281
 
CEBPalpha mutations in childhood acute myeloid leukemia.
Liang DC, Shih LY, Huang CF, Hung IJ, Yang CP, Liu HC, Jaing TH, Wang LY, Chang WH
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (3) : 410-414.
PMID 15618961
 
C/EBPalpha and the pathophysiology of acute myeloid leukemia.
Mueller BU, Pabst T
Current opinion in hematology. 2006 ; 13 (1) : 7-14.
PMID 16319681
 
CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
Paz-Priel I, Cai DH, Wang D, Kowalski J, Blackford A, Liu H, Heckman CA, Gombart AF, Koeffler HP, Boxer LM, Friedman AD
Molecular cancer research : MCR. 2005 ; 3 (10) : 585-596.
PMID 16254192
 
Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage.
Porse BT, Bryder D, Theilgaard-Mˆnch K, Hasemann MS, Anderson K, Damgaard I, Jacobsen SE, Nerlov C
The Journal of experimental medicine. 2005 ; 202 (1) : 85-96.
PMID 15983063
 
Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia.
Sellick GS, Spendlove HE, Catovsky D, Pritchard-Jones K, Houlston RS
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005 ; 19 (7) : 1276-1278.
PMID 15902292
 
Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY, Huang CF, Lin TL, Wu JH, Wang PN, Dunn P, Kuo MC, Tang TC
Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 ; 11 (5) : 1821-1826.
PMID 15756005
 
AML patients with CEBPalpha mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples.
Shih LY, Liang DC, Huang CF, Wu JH, Lin TL, Wang PN, Dunn P, Kuo MC, Tang TC
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2006 ; 20 (4) : 604-609.
PMID 16453003
 
Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia.
Smith LL, Pearce D, Smith ML, Jenner M, Lister TA, Bonnet D, Goff L, Fitzgibbon J
British journal of haematology. 2006 ; 133 (1) : 103-105.
PMID 16512836
 
Involvement of the CEBP gene family in four IGH@ chromosomal translocations in B-Cell precursor acute lymphoblastic leukemia (BCP-ALL).
Dyer MJS, Akasaka T, Balasas T, Russell L, Sugimoto K, Majid A, Brown DG, Cain K, Strefford JC, Harrison CJ, Siebert R
Abstract..
 
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

Contributor(s)

Written05-2006Lan-Lan Smith
Cancer Research UK Medical Oncology Unit, Charterhouse Square, Barts and the London School of Medicine and Dentistry, London, UK

Citation

This paper should be referenced as such :
Smith LL . CEBPA (CCAAT enhancer binding protein alpha). Atlas Genet Cytogenet Oncol Haematol. May 2006 .
URL : http://AtlasGeneticsOncology.org/Genes/CEBPAID40050ch19q13.html

This paper is referenced by INIST as such :
http://documents.irevues.inist.fr/bitstream/2042/38341/1/05-2006-CEBPAID40050ch19q13.pdf   [ Bibliographic record ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Fri Jun 14 16:50:55 CEST 2013
Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.